AegirBio AB Logo

AegirBio AB

Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.

AEGIR | ST

Overview

Corporate Details

ISIN(s):
SE0014401121 (+3 more)
LEI:
549300MWGS283WZLYI10
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Magnasense AB, formerly AegirBio AB, is a diagnostics company specializing in developing innovative, saliva-based solutions for health monitoring. The company's core technology platform enables the creation of user-friendly, non-invasive tests for personalized diagnostics. Magnasense focuses on preventative care, such as oral health, and chronic disease management, particularly through Therapeutic Drug Monitoring (TDM) to optimize the dosage of biological drugs. Its products are designed for both professional healthcare settings and at-home use, aiming to make precision diagnostic testing more accessible, simple, and convenient for individuals and providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AegirBio AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AegirBio AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AegirBio AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-04 Bradley Messmer Other Other 499,829 N/A
2023-01-16 Fredrik Häglund Other Other 45,244 85,511.16 SEK
2022-12-09 Raphaela Heussen Other Other 37,689 N/A
2021-10-27 Martin Linde Other Other 370,000 N/A
2021-10-26 Anders Ingvarsson Other Other 120,000 N/A
2021-09-22 Patrik Elfwing Other Buy 2,000 519,200.00 SEK
2021-09-16 Anders Ingvarsson Other Other 120,000 N/A
2021-06-28 Gunnar Telhammar Other Sell 460 47,288.00 SEK
2021-06-17 Fredrik Häglund Other Other 245,397 1,840,477.50 SEK
2021-06-17 Martin Linde Other Other 160,263 1,169,919.90 SEK

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.